EE694 The Cost-Effectiveness of Targeted-Release Form (TRF)-Budesonide for the Treatment of Adult Population With Immunoglobulin A Nephropathy (IgAN) in Greece
Dec 1, 2025, 00:00
10.1016/j.jval.2025.09.1075
https://www.valueinhealthjournal.com/article/S1098-3015(25)03632-0/fulltext
Title :
EE694 The Cost-Effectiveness of Targeted-Release Form (TRF)-Budesonide for the Treatment of Adult Population With Immunoglobulin A Nephropathy (IgAN) in Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)03632-0&doi=10.1016/j.jval.2025.09.1075
First page :
Section Title :
Open access? :
No
Section Order :
10615